Limits...
CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway.

Zheng J, Fu R, Li J, Wang X - J. Exp. Clin. Cancer Res. (2011)

Bottom Line: To explore the potential role of CpG motif-containing oligonucleotides (CpG-ODN) in modulating the expression of FasL in HepG2 and Fas in Jurkat cells in vitro, and to examine the effect of CpG-ODN treatment on the HepG2 cells-mediated Jurkat cell apoptosis in vitro.Pre-treatment of HepG2 or Jurkat cells with CpG-ODN significantly reduced the frequency of HepG2-mediated apoptotic Jurkat cells and inhibited the activation of caspase-3 in Jurkat cells in vitro.Apparently, CpG-ODN treatment may be a potential therapeutic reagent for HCC.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Clinical Laboratory, the Second Affiliated hospital of Nanchang University, Nanchang 330006, China.

Show MeSH

Related in: MedlinePlus

Treatment with CpG-ODN inhibited the expression of FasL in HepG2 cells in a dose- and time-dependent manner. (A) Dose effect. HepG2 cells were treated with different concentrations of CpG-ODN for 48 h. (B) Time effect. HepG2 cells were treated with 1 μM CpG-ODN for the indicated time periods. The cells were harvested, and the frequency of FasL-positive cells was determined by FACS analysis. Data are expressed as mean% ± SEM of each group of the cells from four independent experiments. *p < 0.05 vs. controls.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3108921&req=5

Figure 1: Treatment with CpG-ODN inhibited the expression of FasL in HepG2 cells in a dose- and time-dependent manner. (A) Dose effect. HepG2 cells were treated with different concentrations of CpG-ODN for 48 h. (B) Time effect. HepG2 cells were treated with 1 μM CpG-ODN for the indicated time periods. The cells were harvested, and the frequency of FasL-positive cells was determined by FACS analysis. Data are expressed as mean% ± SEM of each group of the cells from four independent experiments. *p < 0.05 vs. controls.

Mentions: To determine the effect of CpG-ODN treatment on the expression of FasL, HepG2 cells were treated with various doses of CpG-ODN (10-4-5 μM) for 12 hours, and the frequency of FasL-positive cells was determined by flow cytometry analysis (Figure 1A). Treatment with the CpG-ODN at 10-3 μM significantly reduced the frequency of FasL-expressing HepG2 cells, and treatment with increased doses of the CpG-ODN further decreased the frequency of FasL positive HepG2 cells in vitro. Furthermore, we found that the effects of treatment with 1 μM CpG-ODN on the expression of FasL in HepG2 cells were time-dependent. Evidentially, treatment with 1 μM CpG-ODN for 8 h reduced the frequency of FasL-expressing HepG2 cells to 28% and treatment for 24 h decreased the frequency of FasL-expressing HepG2 cells to near 10%. Apparently, treatment with CpG-ODN inhibited the expression of FasL in HepG2 cells in a dose- and time-dependent manner.


CpG oligonucleotides suppress HepG2 cells-induced Jurkat cell apoptosis via the Fas-FasL-mediated pathway.

Zheng J, Fu R, Li J, Wang X - J. Exp. Clin. Cancer Res. (2011)

Treatment with CpG-ODN inhibited the expression of FasL in HepG2 cells in a dose- and time-dependent manner. (A) Dose effect. HepG2 cells were treated with different concentrations of CpG-ODN for 48 h. (B) Time effect. HepG2 cells were treated with 1 μM CpG-ODN for the indicated time periods. The cells were harvested, and the frequency of FasL-positive cells was determined by FACS analysis. Data are expressed as mean% ± SEM of each group of the cells from four independent experiments. *p < 0.05 vs. controls.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3108921&req=5

Figure 1: Treatment with CpG-ODN inhibited the expression of FasL in HepG2 cells in a dose- and time-dependent manner. (A) Dose effect. HepG2 cells were treated with different concentrations of CpG-ODN for 48 h. (B) Time effect. HepG2 cells were treated with 1 μM CpG-ODN for the indicated time periods. The cells were harvested, and the frequency of FasL-positive cells was determined by FACS analysis. Data are expressed as mean% ± SEM of each group of the cells from four independent experiments. *p < 0.05 vs. controls.
Mentions: To determine the effect of CpG-ODN treatment on the expression of FasL, HepG2 cells were treated with various doses of CpG-ODN (10-4-5 μM) for 12 hours, and the frequency of FasL-positive cells was determined by flow cytometry analysis (Figure 1A). Treatment with the CpG-ODN at 10-3 μM significantly reduced the frequency of FasL-expressing HepG2 cells, and treatment with increased doses of the CpG-ODN further decreased the frequency of FasL positive HepG2 cells in vitro. Furthermore, we found that the effects of treatment with 1 μM CpG-ODN on the expression of FasL in HepG2 cells were time-dependent. Evidentially, treatment with 1 μM CpG-ODN for 8 h reduced the frequency of FasL-expressing HepG2 cells to 28% and treatment for 24 h decreased the frequency of FasL-expressing HepG2 cells to near 10%. Apparently, treatment with CpG-ODN inhibited the expression of FasL in HepG2 cells in a dose- and time-dependent manner.

Bottom Line: To explore the potential role of CpG motif-containing oligonucleotides (CpG-ODN) in modulating the expression of FasL in HepG2 and Fas in Jurkat cells in vitro, and to examine the effect of CpG-ODN treatment on the HepG2 cells-mediated Jurkat cell apoptosis in vitro.Pre-treatment of HepG2 or Jurkat cells with CpG-ODN significantly reduced the frequency of HepG2-mediated apoptotic Jurkat cells and inhibited the activation of caspase-3 in Jurkat cells in vitro.Apparently, CpG-ODN treatment may be a potential therapeutic reagent for HCC.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Clinical Laboratory, the Second Affiliated hospital of Nanchang University, Nanchang 330006, China.

Show MeSH
Related in: MedlinePlus